No high-risk R&D – products acquired from R&D companies
No in-house manufacturing to reduce risk and costs
Scalable business model with low capex needs
Fast-growing global specialist company
Established in 2010, Primex owns, markets and sells high- quality anaesthetic pharmaceuticals worldwide.
Primex’s activities consist of managing two core functions: global regulatory affairs and global distribution and marketing. Manufacturing is outsourced to partners under the strictest quality controls, ensuring full financial flexibility, as a result, the company does not support R&D risk.
The company is building a strong niche offering in anaesthetics and recently acquired global rights to OZALIN, a drug addressing unmet needs in paediatric sedation.
Primex has experienced strong growth since its foundation, developing a lean business model enabling quick scalability through acquisitions of new drugs.